MAManal Abdel-Mageed

Manal Abdel-Mageed

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Manal Abdel-Mageed has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association between atherogenic index of plasma and metabolic dysfunction-associated steatotic liver disease in Egyptian population: a case–control study

    by Manal Abdel-Mageed, Marium Shamaa, Marina Labane, Nehal Elmansoury, Ahmed Wahid

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is hepatic steatosis concurrent with metabolic abnormalities like obesity, insulin resistance, dyslipidemia, and hypertension. We aimed to investigate the association of atherogenic index of plasma with metabolic dysfunction-associated steatotic liver disease (MASLD). The study included 156 MASLD subjects diagnosed by B-ultrasonography having ≥ one of cardiometabolic risk factors while excluding other liver diseases and 144 healthy controls. To all participants; lipid profile, liver enzymes, serum adiponectin and basal insulin level were measured. Calculation of BMI, AIP, LDL cholesterol, Homeostatic model assessment of insulin resistance (HOMA-IR), Fatty liver index (FLI) and Fibrosis-4 (FIB-4) score were done. Receiver operating characteristic curve was drawn to discriminate diagnostic performance of variables. In patients with MASLD, AIP was significantly correlated with increased age, HOMA-IR, FLI, decreased serum adiponectin, and low HDL-C. In multivariate analysis, after adjustment of BMI, LDL-C, HOMA-IR and serum adiponectin, AIP was associated with 3.67 more risk for MASLD (highest OR). To discriminate MASLD, the AUC for AIP was 0.719 (p < 0.001) at cut-off point of > 0.372, while AUC for Combination of AIP and BMI in total MASLD group was 0.865 and for overweight and obese patients was 0.937. Atherogenic index of plasma is independently and positively associated with MASLD, more degree of hepatic steatosis, insulin resistance and low adiponectin level. Using AIP alone or in combination with BMI could alarm clinicians to further investigate for presence of MASLD in individuals at outpatient clinics.

  • Open Access

    Relevance of PNPLA3, TM6SF2, HSD17B13, and GCKR Variants to MASLD Severity in an Egyptian Population

    by Nehal Elmansoury, Ahmed A. Megahed, Ahmed Kamal, Nefertiti El-Nikhely, Marina Labane, Manal Abdelmageed, Ann K. Daly, Ahmed Wahid

    Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a frequent clinical condition globally. Single nucleotide polymorphisms (SNPs) associated with NAFLD have been proposed in the literature and based on bioinformatic screening. The association between NAFLD and genetic variants in Egyptians is still unclear. Hence, we sought to investigate the association of some genetic variants with NAFLD in Egyptians. Egyptians have been categorized into either the MASLD group (n = 205) or the healthy control group (n = 187). The severity of hepatic steatosis and liver fibrosis was assessed by a Fibroscan device. TaqMan-based genotyping assays were employed to explore the association of selected SNPs with MASLD. PNPLA3 rs738409 C>G variant is associated with the presence of MASLD with liver fibrosis, the severity of both hepatic steatosis and liver fibrosis, increased systolic and diastolic blood pressure and increased alanine aminotransferase (all p < 0.05), while the TM6SF2 rs58542926 C>T, HSD17B13 rs9992651 G>A, and GCKR rs1260326 T>C variants were not (all p > 0.05). The TM6SF2 rs58542926 T allele is associated with increased fasting blood glucose and a decreased waist circumference. The GCKR rs1260326 C allele is associated with decreased aspartate transaminase and diastolic blood pressure (all p < 0.05). Only after adjusting for the risk factors (age, sex, BMI, WC, HDL, TG, diabetes mellitus, and hypertension) F2 liver fibrosis score is negatively correlated with the HSD17B13 rs9992651 GA genotype. This study offers evidence for the association of the PNPLA3 rs738409 C>G variant with MASLD among Egyptians and for the association of the PNPLA3 rs738409 G allele, the TM6SF2 rs58542926 T allele, and the GCKR rs1260326 C allele with some parameters of cardiometabolic criteria.